• Topics

  • Formats

Published 23 July 2026

The FDA's own AI asked a pharma company for clinical trial data from a trial that never existed. Martin King (40+ years, FDA/EMA/MDR/IVDR) explains why LLM outputs look fine on paper but can't be defended on audit and what a real regulatory submission workflow looks like.

Reading this content is completely free

Enjoy Unlimited Access and Unlock
Additional Features with a Free Account

Join Now

You are attempting to log out of MyMA

Do you really want to log out?